solagran announcement out, page-2

Good summary of CGNC at the end :)

Where are the downrampers today? Billy Bob the self proclaimed "Biotech Guru" - do you have anything to say to the compound information contained in CGNC? LOL.


CONCLUSIONS AND THERAPEUTIC INDICATIONS


1. CGNC is obtained from green conifer needles using the technology originally
developed by F.T. Solodky. The active principles of CGNC include chlorophyll
derivatives, carotenoids, vitamins E and K, phytosterols, polyprenols, squalene, and a
complex of phytoncidal compounds contained in green conifer needles.

2. CGNC has proven antimicrobial, immunostimulating, antioxidant, hematogenic,
regeneration-stimulating, anti-atherosclerotic, and anticarcinogenic properties.

3. CGNC is recommended for increasing non-specific immune response and as an
additional source of dietary chlorophyll, carotenoids, vitamin E and phytosterols.

4. CGNC and CGNC-based products were successfully tested in clinical trials at leading
Russian hospitals, specializing in different fields of medicine. These trials served as the
basis for delineating the list of therapeutic indications and for concurring the prescribing
guidelines.

5. CGNC is recommended for prevention, and as an adjuvant in the treatment of
infectious diseases. CGNC may be used for prevention of influenza and other ARVI’s.
CGNC is indicated for improving immune status in healthcare workers exposed to TB
carriers, as well as an adjuvant in the treatment of chronic viral hepatitis,
helicobacteriosis and other infections. CGNC is also indicated as an adjuvant in
treatment of intestinal dysbiosis.

6. CGNC is indicated for patients with cardiovascular disease, for correction of moderate
disorders of lipid metabolism.

7. CGNC is indicated for reducing the risk of developing oncological disorders, in
particular, for patients with atrophic gastritis, considered a precancerous disorder of the
stomach.

8. CGNC is recommended for normalisation of hematogenesis: to increase hemoglobin
and erythrocyte counts, for protecting leucocyte production after toxic exposure, for
example, for cancer chemotherapy patients.

9. CGNC is indicated as an adjuvant in the treatment of chronic pulmonary disease and
chronic GI tract disorders.

10. The recommended CGNC dose for internal use for adults and children 12 and older is
0.3-0.6 g per day. The standard course is 1-3 months, which may be extended to 6
months or longer. With chronic diseases, CGNC is indicated after basic therapy, as an
adjuvant in the recovery / convalescence / rehabilitation treatment program.

11. CGNC can be applied topically to the skin or mucosa for acceleration of wound healing,
and as an active ingredient in toothpaste formulations for prevention and treatment of
periodontal disorders.

12. CGNC is a safe substance, and in clinical use it has not led to any adverse drug
reactions or significant side effects. CGNC is contraindicated in rare cases of individual
intolerance.